TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TEVA - US8816242098 - ADR
32.35 USD
-0.29 (-0.89%)
32.4 USD
+0.05 (+0.15%)
Taking everything into account, TEVA scores 4 out of 10 in our fundamental rating. TEVA was compared to 190 industry peers in the Pharmaceuticals industry. TEVA scores excellent on profitability, but there are concerns on its financial health. TEVA has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
- TEVA had positive earnings in the past year.
- TEVA had a positive operating cash flow in the past year.
- In the past 5 years TEVA reported 4 times negative net income.
- TEVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 1.79%, TEVA belongs to the top of the industry, outperforming 81.58% of the companies in the same industry.
- TEVA has a Return On Equity of 9.82%. This is amongst the best in the industry. TEVA outperforms 84.74% of its industry peers.
- With an excellent Return On Invested Capital value of 10.63%, TEVA belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for TEVA is below the industry average of 12.84%.
- The last Return On Invested Capital (10.63%) for TEVA is above the 3 year average (9.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.79% | ||
| ROE | 9.82% | ||
| ROIC | 10.63% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
1.3 Margins
- Looking at the Profit Margin, with a value of 4.24%, TEVA belongs to the top of the industry, outperforming 81.05% of the companies in the same industry.
- Looking at the Operating Margin, with a value of 22.76%, TEVA belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
- TEVA's Operating Margin has improved in the last couple of years.
- TEVA has a Gross Margin of 51.33%. This is in the better half of the industry: TEVA outperforms 64.74% of its industry peers.
- TEVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.76% | ||
| PM (TTM) | 4.24% | ||
| GM | 51.33% |
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
2. Health
2.1 Basic Checks
- TEVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for TEVA has been increased compared to 1 year ago.
- Compared to 5 years ago, TEVA has more shares outstanding
- Compared to 1 year ago, TEVA has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 0.96, we must say that TEVA is in the distress zone and has some risk of bankruptcy.
- TEVA's Altman-Z score of 0.96 is in line compared to the rest of the industry. TEVA outperforms 51.05% of its industry peers.
- TEVA has a debt to FCF ratio of 29.05. This is a negative value and a sign of low solvency as TEVA would need 29.05 years to pay back of all of its debts.
- The Debt to FCF ratio of TEVA (29.05) is better than 74.74% of its industry peers.
- TEVA has a Debt/Equity ratio of 2.32. This is a high value indicating a heavy dependency on external financing.
- The Debt to Equity ratio of TEVA (2.32) is worse than 78.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 29.05 | ||
| Altman-Z | 0.96 |
ROIC/WACC1.32
WACC8.05%
2.3 Liquidity
- TEVA has a Current Ratio of 1.11. This is a normal value and indicates that TEVA is financially healthy and should not expect problems in meeting its short term obligations.
- TEVA has a worse Current ratio (1.11) than 82.63% of its industry peers.
- TEVA has a Quick Ratio of 1.11. This is a bad value and indicates that TEVA is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.82, TEVA is not doing good in the industry: 81.58% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
- The earnings per share for TEVA have decreased by -3.96% in the last year.
- Measured over the past years, TEVA shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.18% on average per year.
- The Revenue has been growing slightly by 0.02% in the past year.
- The Revenue has been decreasing by -0.41% on average over the past years.
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)0.02%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
3.2 Future
- The Earnings Per Share is expected to grow by 8.13% on average over the next years. This is quite good.
- Based on estimates for the next years, TEVA will show a small growth in Revenue. The Revenue will grow by 1.76% on average per year.
EPS Next Y8.54%
EPS Next 2Y5.56%
EPS Next 3Y8.13%
EPS Next 5YN/A
Revenue Next Year3.29%
Revenue Next 2Y1.8%
Revenue Next 3Y1.76%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 11.94, which indicates a very decent valuation of TEVA.
- Compared to the rest of the industry, the Price/Earnings ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 88.42% of the companies listed in the same industry.
- TEVA is valuated cheaply when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 11.49, the valuation of TEVA can be described as reasonable.
- TEVA's Price/Forward Earnings ratio is rather cheap when compared to the industry. TEVA is cheaper than 86.32% of the companies in the same industry.
- TEVA is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.31, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.94 | ||
| Fwd PE | 11.49 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 87.37% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, TEVA is valued a bit cheaper than the industry average as 77.37% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 64.2 | ||
| EV/EBITDA | 10.77 |
4.3 Compensation for Growth
- TEVA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- TEVA has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.4
PEG (5Y)N/A
EPS Next 2Y5.56%
EPS Next 3Y8.13%
5. Dividend
5.1 Amount
- TEVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
32.35
-0.29 (-0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/dmh
Earnings (Next)01-28 2026-01-28/bmo
Inst Owners14.54%
Inst Owner Change-0.89%
Ins Owners0.42%
Ins Owner Change-1.57%
Market Cap37.11B
Revenue(TTM)16.78B
Net Income(TTM)712.00M
Analysts82.86
Price Target0.11 (-99.66%)
Short Float %4%
Short Ratio4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.58%
Min EPS beat(2)4.65%
Max EPS beat(2)16.51%
EPS beat(4)4
Avg EPS beat(4)7.25%
Min EPS beat(4)2.01%
Max EPS beat(4)16.51%
EPS beat(8)7
Avg EPS beat(8)7.06%
EPS beat(12)8
Avg EPS beat(12)1.63%
EPS beat(16)10
Avg EPS beat(16)1.03%
Revenue beat(2)1
Avg Revenue beat(2)-1.93%
Min Revenue beat(2)-4.77%
Max Revenue beat(2)0.9%
Revenue beat(4)2
Avg Revenue beat(4)-1.98%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)0.9%
Revenue beat(8)5
Avg Revenue beat(8)0.57%
Revenue beat(12)7
Avg Revenue beat(12)0.43%
Revenue beat(16)7
Avg Revenue beat(16)-1.36%
PT rev (1m)60.86%
PT rev (3m)101.92%
EPS NQ rev (1m)-1.43%
EPS NQ rev (3m)-4.19%
EPS NY rev (1m)0.28%
EPS NY rev (3m)3.17%
Revenue NQ rev (1m)-0.66%
Revenue NQ rev (3m)-0.88%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)0.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.94 | ||
| Fwd PE | 11.49 | ||
| P/S | 2.21 | ||
| P/FCF | 64.2 | ||
| P/OCF | 34.81 | ||
| P/B | 5.12 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.77 |
EPS(TTM)2.71
EY8.38%
EPS(NY)2.82
Fwd EY8.7%
FCF(TTM)0.5
FCFY1.56%
OCF(TTM)0.93
OCFY2.87%
SpS14.62
BVpS6.32
TBVpS-11.01
PEG (NY)1.4
PEG (5Y)N/A
Graham Number19.63
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.79% | ||
| ROE | 9.82% | ||
| ROCE | 13.46% | ||
| ROIC | 10.63% | ||
| ROICexc | 11.52% | ||
| ROICexgc | 47.85% | ||
| OM | 22.76% | ||
| PM (TTM) | 4.24% | ||
| GM | 51.33% | ||
| FCFM | 3.45% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
ROICexc(3y)10.21%
ROICexc(5y)9.09%
ROICexgc(3y)56.98%
ROICexgc(5y)49.9%
ROCE(3y)11.55%
ROCE(5y)10.49%
ROICexgc growth 3Y25.78%
ROICexgc growth 5Y17.24%
ROICexc growth 3Y15.91%
ROICexc growth 5Y18.91%
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
F-Score7
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 29.05 | ||
| Debt/EBITDA | 3.48 | ||
| Cap/Depr | 48.27% | ||
| Cap/Sales | 2.91% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 22.08% | ||
| Profit Quality | 81.18% | ||
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | 0.96 |
F-Score7
WACC8.05%
ROIC/WACC1.32
Cap/Depr(3y)44.85%
Cap/Depr(5y)42.78%
Cap/Sales(3y)3.33%
Cap/Sales(5y)3.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y8.54%
EPS Next 2Y5.56%
EPS Next 3Y8.13%
EPS Next 5YN/A
Revenue 1Y (TTM)0.02%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
Revenue Next Year3.29%
Revenue Next 2Y1.8%
Revenue Next 3Y1.76%
Revenue Next 5YN/A
EBIT growth 1Y-3.39%
EBIT growth 3Y1.63%
EBIT growth 5Y5.48%
EBIT Next Year17.74%
EBIT Next 3Y9.96%
EBIT Next 5YN/A
FCF growth 1Y-4.93%
FCF growth 3Y46.96%
FCF growth 5Y27.42%
OCF growth 1Y-7.87%
OCF growth 3Y16.04%
OCF growth 5Y10.76%
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What is the fundamental rating for TEVA stock?
ChartMill assigns a fundamental rating of 4 / 10 to TEVA.
What is the valuation status of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
ChartMill assigns a valuation rating of 7 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.
Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 7 / 10.
What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 11.94 and the Price/Book (PB) ratio is 5.12.
What is the earnings growth outlook for TEVA PHARMACEUTICAL-SP ADR?
The Earnings per Share (EPS) of TEVA PHARMACEUTICAL-SP ADR (TEVA) is expected to grow by 8.54% in the next year.